Vinay Prasad has resumed leadership of the FDA’s Center for Biologics Evaluation and Research just weeks after his abrupt departure amid tensions related to Sarepta Therapeutics’ gene therapy for Duchenne muscular dystrophy. This rapid return reflects internal regulatory pressures following disputes over vaccine, gene therapy, and blood product oversight. The circumstances involve political controversies and public criticism influenced by outside actors, highlighting ongoing challenges within FDA leadership and regulatory consensus.